A Dose Escalation Study of Experimental RMC-4630 for Relapsed/Refractory Solid Tumors
a study on Solid Tumor
Solid Tumors SHP2 PTPN11 NSCLC EGFR RTK KRAS G12 BRAF Class 3 NF1 LOF advanced solid tumor advanced solid malignancies melanoma skin cancer ovarian cancer pancreatic cancer endometrium/uterus cancer bladder cancer cervical cancer Carcinoma, Non-Small-Cell Lung Neoplasms, Squamous Cell Carcinoma, Squamous Cell Esophageal Neoplasms Carcinoma, Bronchogenic Bronchial Neoplasms Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Neoplasms, Glandular and Epithelial Gastrointestinal Neoplasms Digestive System Neoplasms Head and Neck Neoplasms Digestive System Diseases Esophageal Diseases Gastrointestinal Diseases RMC-4630
Lead Scientists at UC Health
- Sai-Hong Ignatius Ou, MD, PhD (uci)
Health Sciences Professor, Medicine. Authored (or co-authored) 5 research publications.
- Jonathan Riess, MD (ucdavis)
Assistant Professor, Hematology and Oncology. Authored (or co-authored) 60 research publications.
- Caroline McCoach, MD (ucsf)
Caroline McCoach is a thoracic oncologist who focuses on the treatment of patients with lung cancer as well as other thoracic malignancies. Her goal is to provide a personalized approach to treatment, based on each patient’s cancer type in combination with their individual treatment goals.
- accepting new patients
- Start Date
- Completion Date
- Revolution Medicines, Inc.
- Phase 1
- Study Type
- Last Updated